Prolymphocytic LeukemiaSymptoms, Doctors, Treatments, Advances & More
Learn About Prolymphocytic Leukemia
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
UT MD Anderson Cancer Center
Tapan Kadia is a Hematologist practicing medicine in Cary, North Carolina. Dr. Kadia is rated as an Elite provider by MediFind in the treatment of Prolymphocytic Leukemia. He is also highly rated in 39 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.
Michael Hallek practices practicing medicine in Koeln, Germany. Mr. Hallek is rated as an Elite expert by MediFind in the treatment of Prolymphocytic Leukemia. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Bone Marrow Transplant, and Bone Graft.
Stephan Stilgenbauer practices practicing medicine in Ulm, Germany. Mr. Stilgenbauer is rated as an Elite expert by MediFind in the treatment of Prolymphocytic Leukemia. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Transplant, and Bone Graft.
Summary: The goal of this clinical research study is to learn if the combination of ruxolitinib with cladribine and venetoclax can help to control the disease in patients with R/R T-PLL.
Summary: This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.